Ozempic vs Wegovy: Same Drug, Different Doses and Uses

Ozempic® and Wegovy® are one drug, semaglutide, made by Novo Nordisk and sold under two brand names for different uses. Ozempic is approved for type 2 diabetes, including lowering heart and kidney risks in people with diabetes. Wegovy is approved for weight management in adults and teens 12 and older, for lowering heart risk in adults with heart disease and overweight, and for a liver disease called MASH. Wegovy also goes to higher doses: 2.4 mg a week, or 7.2 mg as Wegovy HD, while Ozempic tops out at 2 mg. In STEP 2, a trial in adults with type 2 diabetes, people lost an average of 9.9% of their weight on Wegovy's dose and 7.2% on an Ozempic dose over 68 weeks. As of November 2026, both cost $349 a month at standard doses through NovoCare, Novo Nordisk's pharmacy.

If you're paying cash for weight loss, there is a third route: compounded semaglutide, $89/mo flat at MaxLife, all-inclusive. It is not FDA-approved, and it is not Ozempic or Wegovy; the compounded section below explains the difference.

Wegovy vs Ozempic at a Glance

Sources: the FDA labels on DailyMed for Ozempic, Wegovy and the Ozempic pill; Drugs@FDA; STEP 2 results on ClinicalTrials.gov; NovoCare; CMS. Prices as of November 2026.

Is Wegovy the Same as Ozempic?

Not exactly. Wegovy and Ozempic both contain semaglutide and are both made by Novo Nordisk, but they are separate FDA-approved products, each with its own label, approved uses, doses, devices and price.

Semaglutide was first approved as Ozempic, for type 2 diabetes, on December 5, 2017. Novo Nordisk then tested it at a higher dose for weight management in the STEP trials, and the FDA approved that use as Wegovy on June 4, 2021. Eli Lilly splits its own medicine, tirzepatide, the way Novo splits semaglutide: Mounjaro® for diabetes and Zepbound® for weight. Our guide to Zepbound vs Mounjaro covers that pair.

In practice, the two brands are not interchangeable. The pens hold different strengths, a prescription names one brand, and insurers cover each brand for its own approved uses. If your question is about compounded semaglutide rather than a brand, our guide to compounded semaglutide vs Ozempic answers it.

What Is the Difference Between Ozempic and Wegovy?

The differences are the approved uses, the doses, the devices and who can take them:

• Approved uses. Ozempic treats type 2 diabetes and lowers the risk of heart attack, stroke, kidney decline and cardiovascular death in adults with type 2 diabetes who have heart or kidney disease. Wegovy is approved for weight management, to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight (no diabetes needed), and, under accelerated approval, for MASH with moderate to advanced liver scarring.
• Doses. Ozempic's maintenance doses are 0.5 mg, 1 mg or 2 mg a week. Wegovy's maintenance dose is 2.4 mg (or 1.7 mg), and adults who tolerate 2.4 mg for at least 4 weeks can move up to 7.2 mg as Wegovy HD.
• Age. Ozempic is for adults; its label says safety and effectiveness in children have not been established. Wegovy injections are approved for adults and for children 12 and older with obesity.
• Devices. Ozempic comes in a multi-dose pen that delivers several weekly doses, and in single-dose prefilled syringes up to 1 mg. Wegovy comes in single-dose pens, a 4-dose Wegovy FlexTouch pen at 2.4 mg and single-dose syringes. Some summaries still say Wegovy uses only single-use pens and Ozempic only multi-use pens; the current labels list more options for both.
• Pills. Both brands now have a daily tablet. The Ozempic pill (1.5 mg, 4 mg or 9 mg) is for type 2 diabetes. The Wegovy pill (1.5 mg up to 25 mg) is for weight management and heart risk. Our guide to the Wegovy pill vs injection compares the two forms.

Which One Is Approved for What?

Each brand gained its uses over time. These are the approval dates listed in Drugs@FDA:

• December 5, 2017: Ozempic, for blood sugar control in type 2 diabetes.
• January 16, 2020: Ozempic, to lower heart risk in type 2 diabetes with heart disease.
• June 4, 2021: Wegovy, for weight management in adults.
• March 28, 2022: Ozempic 2 mg.
• December 23, 2022: Wegovy, for teens 12 and older.
• March 8, 2024: Wegovy, to lower heart risk in adults with heart disease and obesity or overweight.
• January 28, 2025: Ozempic, to lower kidney and heart risks in type 2 diabetes with chronic kidney disease.
• August 15, 2025: Wegovy, for MASH with moderate to advanced liver scarring.
• December 22, 2025: the Wegovy pill.
• March 19, 2026: Wegovy HD, 7.2 mg (FDA).

Is Wegovy Stronger Than Ozempic for Weight Loss?

Yes, at the doses each brand uses. Wegovy's usual maintenance dose, 2.4 mg, is higher than Ozempic's top dose, 2 mg, and higher doses of semaglutide produced more weight loss in trials. The closest thing to a head-to-head test is STEP 2, published in The Lancet in 2021. It randomly assigned 1,210 adults with type 2 diabetes and overweight or obesity to semaglutide 2.4 mg (Wegovy's dose), semaglutide 1.0 mg (an Ozempic dose) or a placebo for 68 weeks, alongside diet and activity counseling.

Sources: ClinicalTrials.gov results for STEP 2 (observed averages) and the Lancet abstract. The paper's model-based estimate for 2.4 mg is 9.6%. The trial was funded by Novo Nordisk.

Two caveats. People with type 2 diabetes usually lose less weight on GLP-1 medicines than people without it, so these numbers are lower than the ones you'll see quoted for Wegovy. And 1.0 mg is not Ozempic's highest dose: in SUSTAIN FORTE, adults with type 2 diabetes lost 6.4 kg (about 14 lb) on Ozempic 2 mg vs 5.6 kg (about 12 lb) on 1 mg over 40 weeks, a difference the Ozempic label calls not statistically significant.

The separate trials agree:

• Wegovy in adults without diabetes (STEP 1): 14.9% weight loss on 2.4 mg vs 2.4% on placebo over 68 weeks (NEJM, 2021).
• Wegovy HD in adults without diabetes: 18.8% on 7.2 mg vs 15.5% on 2.4 mg and 3.9% on placebo over 72 weeks, according to the Wegovy label.
• Wegovy HD in adults with type 2 diabetes: 13.2% on 7.2 mg vs 10.4% on 2.4 mg and 3.8% on placebo over 72 weeks, according to the same label.
• Ozempic in its diabetes trials: adults lost an average of 3.2 kg to 6.4 kg (about 7 to 14 lb) over 30 to 56 weeks, depending on the trial and dose, according to the Ozempic label.

These results belong to the brand products and doses studied. They have not been shown for compounded semaglutide.

Ozempic vs Wegovy Dosage: How Do the Doses Compare?

Both start at 0.25 mg a week for 4 weeks and then move to 0.5 mg, but after that the ladders split: Ozempic stops at 2 mg, while Wegovy climbs to 2.4 mg, or 7.2 mg for some adults. These are the label schedules:

Sources: Ozempic and Wegovy labels on DailyMed, as of November 2026.

There is no official Ozempic-to-Wegovy conversion chart, and neither label gives one. The devices aren't interchangeable either: an Ozempic pen delivers several weekly doses from one cartridge, while most Wegovy pens hold a single fixed dose. The Wegovy label adds one rule worth knowing: if you miss 2 or more doses in a row, your prescriber restarts the dose increase at a lower dose to limit stomach side effects.

The pills follow their own schedules. Both are taken once a day on an empty stomach with up to 4 ounces of water, at least 30 minutes before food, drink or other pills. The Wegovy pill rises from 1.5 mg to 4 mg to 9 mg, a month each, then 25 mg; the label lets adults on Wegovy 2.4 mg injections switch to the 25 mg pill one week after their last shot. The Ozempic pill comes in 1.5 mg, 4 mg and 9 mg and is not interchangeable milligram for milligram with Rybelsus®, Novo's older semaglutide tablet. Our semaglutide dosage chart shows every step.

Do Ozempic and Wegovy Have Different Side Effects?

They share the side effects of semaglutide, mostly nausea, diarrhea, vomiting and constipation, but Wegovy's label reports higher rates. That is mainly because Wegovy's trials used a higher dose, ran longer and enrolled people without diabetes. Here are the label numbers, with placebo rates in parentheses:

Sources: Ozempic label, Table 1, and Wegovy label, Table 3 and section 6.1 (DailyMed, as of November 2026).

Both labels say rates from one drug's trials can't be directly compared with another's. In STEP 2, where the same kind of patients got both doses, stomach side effects were somewhat more common on 2.4 mg than on 1.0 mg (63.5% vs 57.5%), and most were mild to moderate. Wegovy HD adds one effect: 22% of people on 7.2 mg reported dysesthesia, a changed skin sensation such as tingling or burning, compared with 6% on 2.4 mg. Most stomach side effects happen while the dose is being raised, which is why both brands start low.

Is Wegovy Safer Than Ozempic?

Neither has been shown to be safer. Because the medicine is semaglutide in both, the labels carry the same boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is not known whether it does in people. Neither should be used if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2).

Both labels also warn about pancreatitis, gallbladder problems, kidney injury from dehydration, severe stomach problems, serious allergic reactions, worsening diabetic eye disease in people with diabetic retinopathy, and the risk of inhaling stomach contents during anesthesia. Low blood sugar is a concern mainly when semaglutide is combined with insulin or a sulfonylurea, which is more common among people taking Ozempic. Both labels say to stop at least 2 months before a planned pregnancy, because semaglutide clears slowly. And on November 9, 2026, the FDA required new warnings about NAION, a rare cause of sudden vision loss in one eye, on all GLP-1 medicines.

Talk to your provider about any side effect that is severe or doesn't settle, and get care right away for severe stomach pain that won't go away or sudden vision loss.

Which Is Cheaper, Ozempic or Wegovy?

At standard doses, they cost the same without insurance: $349 a month each through NovoCare as of November 2026. The difference is at the top of the ladder. Ozempic 2 mg costs $499 a month, more than Wegovy 2.4 mg at $349, and Wegovy HD costs $399.

Sources: NovoCare for Ozempic and Wegovy. Savings offers exclude Medicare, Medicaid and other government coverage, and Novo Nordisk can change them at any time.

A month of Ozempic is one pen; a month of Wegovy is four single-dose pens. List prices, which matter if your insurance has a deductible or coinsurance, are about to change too: Novo Nordisk announced that on January 1, 2027, the list price of Ozempic and Wegovy drops to $675 a month, about 35% lower for Ozempic and 50% lower for Wegovy, and that the change does not affect its self-pay prices. Our semaglutide cost guide compares every route.

Why Does Insurance Cover Ozempic but Not Wegovy?

Coverage follows the approved use on the label. Diabetes medicines are a standard benefit, so most plans cover Ozempic for type 2 diabetes, often after confirming the diagnosis. Weight-management drugs are a separate benefit that many plans exclude, so one plan can pay for Ozempic for diabetes and deny Wegovy for weight. Prescribing Ozempic for weight alone is off-label, and insurers usually won't pay for it.

Wegovy's other uses can change the answer. Because Wegovy is approved to lower heart risk in adults with heart disease and overweight, and for MASH, a plan may cover it for those conditions even if it excludes weight-loss drugs.

Medicare splits the two brands by condition:

• Part D plans can cover Ozempic for type 2 diabetes, and Wegovy for heart-risk reduction or MASH.
• The Medicare GLP-1 Bridge, a CMS program from July 1, 2026 to December 31, 2027, covers weight-management use for a $50 copay. It includes Wegovy injections and pills, the Zepbound KwikPen and Foundayo™, but not Ozempic. You need a BMI of 35 or more, or a lower BMI with certain conditions (CMS).
• People with type 2 diabetes can't use the Bridge. CMS says their Part D plan may cover a GLP-1 for diabetes instead.

If you take Ozempic for diabetes and want Wegovy for weight, your plan will review Wegovy as a new request, usually with prior authorization. Our guide to weight-loss drugs covered by insurance explains how plans decide.

Can You Switch From Ozempic to Wegovy?

Yes, with a new prescription, but neither label describes how to move from one brand to the other, so your prescriber decides the dose and the timing. The switch usually comes up when weight, rather than blood sugar, becomes the main goal, or when coverage changes.

What applies to any switch:

• No conversion chart. The Wegovy label has one dose-increase schedule, starting at 0.25 mg. Whether you start there or at a higher step depends on your current Ozempic dose, how long it has been since your last shot and how well you tolerate it.
• Diabetes needs a plan. If you have type 2 diabetes, the Wegovy label says to check your blood sugar before starting and during treatment. If you also take insulin or a sulfonylurea, your prescriber may lower that dose to prevent low blood sugar.
• Coverage comes first. A new brand means a new insurance review, and Wegovy for weight often needs prior authorization.
• The reverse happens too. People move from Wegovy to Ozempic after a type 2 diabetes diagnosis, usually because their plan covers Ozempic.

Can You Take Ozempic and Wegovy Together?

No. The Wegovy label says it should not be used with other semaglutide products or with any other GLP-1 medicine, and Ozempic is semaglutide. Taking both doubles the dose and the risk of nausea, vomiting and dehydration, with no proven benefit. If you see more than one prescriber, make sure each one has your full medication list.

Where Does Compounded Semaglutide Fit?

Compounded semaglutide is neither Ozempic nor Wegovy. Compounded semaglutide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. It is not made by Novo Nordisk, and as of November 2026 there is no FDA-approved generic of Ozempic or Wegovy on the market.

It also differs in practice. Compounded semaglutide usually comes in a multi-dose vial at a concentration the pharmacy sets, drawn with a syringe. In an August 12, 2026 letter to state medical boards, the FDA warned that compounded GLP-1 products often come in different concentrations from the brands, so dose volumes are not interchangeable. The FDA ended the semaglutide shortage on February 21, 2025, and it says a compounded drug "might be appropriate if a patient's medical need cannot be met by an FDA-approved drug" (FDA). The STEP and SUSTAIN results above belong to Wegovy and Ozempic; these results have not been shown for compounded semaglutide.

Price is the reason people ask. Be clear about the trade: you pay less than for self-pay Ozempic or Wegovy, and you give up FDA approval, insurance coverage and a prefilled pen. Compounded semaglutide through MaxLife is offered for weight management, not as a treatment for type 2 diabetes, so if you have diabetes, keep your diabetes care with the clinician who manages it.

Here is how MaxLife works. MaxLife is a telehealth patient management platform, not a pharmacy or drug maker. The online intake takes about 2 minutes. A licensed provider reviews your online intake, health history and clinical records, usually within 24 hours, can follow up with questions, and you can ask for a video visit. The provider considers everything in your record, including diabetes and your other medicines, and decides case by case. If compounded semaglutide is right for you, a licensed partner pharmacy prepares it and ships it with free expedited shipping, in all 50 states. It costs $89/mo flat: all-inclusive (the provider's review and follow-up, the medicine if prescribed, and supplies), the same price at every dose, with no membership fee. No insurance is needed, and HSA and FSA funds may be eligible. If you're also weighing tirzepatide, our guide to semaglutide vs tirzepatide compares the two medicines.

Ozempic or Wegovy: Which Should You Ask About?

Your diagnosis and how you'll pay decide which brand to ask about. Use this as a starting point with your prescriber:

• Type 2 diabetes: ask about Ozempic, the brand approved for diabetes, which most plans cover for that use. If you're choosing between diabetes medicines, see Trulicity vs Ozempic.
• Type 2 diabetes with chronic kidney disease: Ozempic is the semaglutide brand with a kidney approval.
• Type 2 diabetes, with weight as a main goal: Wegovy is approved for weight management in adults with type 2 diabetes too, and it produced more weight loss than an Ozempic dose in STEP 2. Coverage often decides.
• Heart disease with overweight, without diabetes: Wegovy is approved to lower your risk of heart attack and stroke. In the SELECT trial, 6.5% of people on Wegovy had a major heart event vs 8.0% on placebo.
• MASH with moderate to advanced liver scarring: Wegovy is the approved brand.
• A teen 12 to 17 with obesity: Wegovy injections are approved for this age; that choice belongs with a pediatric specialist. MaxLife's program is for adults.
• Weight loss, and your plan covers weight-loss drugs: ask about Wegovy, usually with prior authorization.
• Weight loss on Medicare: ask whether you qualify for Wegovy through the $50 Medicare GLP-1 Bridge.
• You'd rather not inject: the Wegovy pill for weight management, or the Ozempic pill for diabetes.
• Weight loss with no coverage: compare NovoCare's Wegovy pen ($349 a month after the new-patient offer) or pill ($149 to $299) with compounded semaglutide ($89/mo flat at MaxLife, not FDA-approved). If you're open to tirzepatide, see Zepbound vs Wegovy.

The Bottom Line

Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic is approved for type 2 diabetes and its heart and kidney risks, in weekly doses up to 2 mg. Wegovy is approved for weight management, heart-risk reduction and MASH, in doses up to 2.4 mg, or 7.2 mg as Wegovy HD, and it produced more weight loss than an Ozempic dose in STEP 2 (9.9% vs 7.2% over 68 weeks in adults with type 2 diabetes). As of November 2026, NovoCare charges $349 a month for either brand at standard doses, $499 for Ozempic 2 mg and $399 for Wegovy HD, and only Wegovy is part of Medicare's $50 GLP-1 Bridge. Never take both, and let your diagnosis and coverage decide which one to ask about.